切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2021, Vol. 15 ›› Issue (02) : 199 -202. doi: 10.3877/cma.j.issn.1674-3946.2021.02.022

所属专题: 文献

论著

Anxa2在乳腺癌细胞侵袭转移中的作用机制及对STAT3信号通路的影响研究
李建丽1, 李永梅1, 康鸿斌1, 王霞1,()   
  1. 1. 010050 呼和浩特,内蒙古医科大学附属医院甲乳外科
  • 收稿日期:2020-06-19 出版日期:2021-04-26
  • 通信作者: 王霞

The mechanism research of Anxa2 mediated invasion and metastasis of breast cancer cell through STAT3 signaling pathway

Jianli Li1, Yongmei Li1, Hongbin Kang1, Xia Wang1,()   

  1. 1. Department of Thyroid and Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050
  • Received:2020-06-19 Published:2021-04-26
  • Corresponding author: Xia Wang
  • Supported by:
    Scientific Research Project of Institutions of Higher Education in Inner Mongolia Autonomous Region(NJZY19102)
引用本文:

李建丽, 李永梅, 康鸿斌, 王霞. Anxa2在乳腺癌细胞侵袭转移中的作用机制及对STAT3信号通路的影响研究[J/OL]. 中华普外科手术学杂志(电子版), 2021, 15(02): 199-202.

Jianli Li, Yongmei Li, Hongbin Kang, Xia Wang. The mechanism research of Anxa2 mediated invasion and metastasis of breast cancer cell through STAT3 signaling pathway[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(02): 199-202.

目的

探讨膜联蛋白A2(Anxa2)在乳腺癌细胞侵袭转移中的作用机制及对转导因子和转录活化因子(STAT3)信号通路的影响。

方法

乳腺癌细胞株MCF-7作为研究对象,分为对照组和转染组。对照组细胞中加入细胞培养基进行培养;转染组细胞分为两组,均常规构建Anxa2野生型表达载体,一组为未转染组;另一组将其转染到Anxa2降表达的细胞进行拯救,并完成细胞转染,设为转染组;采用细胞划痕试验和Transwell小室完成两组细胞划痕试验、侵袭和迁移试验;采用实时荧光PCR技术测定两组细胞STAT3信号通路水平。采用SPSS18.0软件处理,STAT3信号通路水平、细胞划痕试验采用(±s)表示,三组数据比较采用F检验,P<0.05差异有统计学意义。

结果

转染组细胞24 h Anxa2降表达后细胞划痕距离大于未转染组与对照组(P<0.05),未转染组与对照组差异无统计学意义(P>0.05);转染组细胞培养后迁移、侵袭能力均低于对照组与未转染组(P<0.05);转染组STAT3 mRNA水平明显低于对照组与未转染组(P<0.05)。

结论

Anxa2降表达在乳腺癌细胞中能抑制细胞的侵袭与转移,可能与抑制STAT3信号通路有关,可能成为乳腺癌治疗提供新的靶点。

Objective

To investigate the role of annexin A2 (anxa2) in mediating invasion and metastasis of breast cancer cells through the signal pathway of transducer and activator of transcription (STAT3).

Methods

Breast cancer cell line MCF-7 was divided into control group and transfection group. The cells in the control group were cultured in the cell culture medium; the cells in the transfection group were divided into two groups, while the wild-type expression vector of anxa2 was routinely constructed, one group was the non-transfection group; the other group was transfected into the cells with decreased expression of anxa2 for rescue, and completed the cell transfection, which was set as the transfection group; the cell scratch test and Transwell chamber were used to complete the two groups of cell scratch test, invasion and migration test The level of STAT3 signaling pathway was measured by real-time PCR. Statistical analysis were performed by using SPSS18.0 software. STAT3 signal pathway level and cell scratch test were expressed as. The data of three groups were analyzed by using F test. A P value of <0.05 was considered as statistically significant difference.

Results

The scratch distance of transfection group was much longer than that of non-transfection group and control group (P<0.05), however without significant difference between non-transfection group and control group (P>0.05); the migration and invasion ability of transfected cells were lower than those of control group and non-transfection group respectively (P<0.05); STAT3 mRNA level of transfected group was lower than those of control group and non-transfection group (P<0.05).

Conclusion

Down regulated expression of anxa2 could inhibit the invasion and metastasis of breast cancer cells, relating to the inhibition of STAT3 signaling pathway, which may provide a new target for the treatment of breast cancer.

表1 STAT3基因引物设计
图1 乳腺癌细胞株MCF-7对照组、未转染组及转染组细胞划痕结果比较
图2 乳腺癌细胞株MCF-7对照组、未转染组及转染组细胞迁移、侵袭结晶紫色染色比较[注:A图、D图为对照组迁移、侵袭结晶紫染色结果;B图、E图为未转染组迁移、侵袭结晶紫染色结果;C图、F图为转染组迁移、侵袭结晶紫染色结果。]
[1]
王瑞鸽,颜子千,邓梓坤,等. MiR-206与ANXA2的3'UTR靶向结合抑制乳腺癌侵袭[J]. 中国生物化学与分子生物学报,2018,34(4):434-439.
[2]
吕峰,李翠,于洋,等. KLF3通过STAT3调控乳腺癌细胞的运动、迁移及侵袭[J].中华医学杂志,2019,99(38):3014-3018.
[3]
Mendez O, Peg V, Salvans C, et al. Abstract 24: Extracell μlar HMGA1 promotes tumor invasion and metastasis in breast cancer[J]. Cancer Research, 2018, 78(13 Supplement): 24.
[4]
高久蕉,张琦,杨永亮.莱菔素通过阻断STAT3信号通路杀伤三阴性乳腺癌细胞MDA-MB-468和MDA-MA-231[J].中国肿瘤生物治疗杂志,2019,26(8):837-844.
[5]
李新,牛冰,李庆辉,等.黄素联合KLF8基因siRNA调控JAK2/STAT3信号通路对乳腺癌细胞生长抑制作用的研究[J].安徽医科大学学报,2019,54(1):69-73.
[6]
Li QT, Feng YM, Ke ZH, et al.KCNN4 promotes invasion and metastasis through the MAPK/ERK pathway in hepatocell μlar carcinoma[J]. Journal of Investigative Medicine, 2019, 68(1): jim-2019-001073.
[7]
马剑锋,张艳彩,孙慧.下调SRGN基因表达对乳腺癌细胞凋亡及JAK/STAT信号通路的影响[J]. 癌症进展,2018,16(6):698-701.
[8]
陈露.Six1基因在乳腺癌组织表达及RNA干扰其表达对癌细胞增殖侵袭能力的影响[J]. 医学分子生物学杂志,2018,15(5):315-319.
[9]
胡潺潺,李青山,刘兰芳,等. RNA干扰UBQLN基因表达对乳腺癌细胞增殖、凋亡、侵袭的影响及机制研究[J]. 中国免疫学杂志,2018,34(9):1315-1320.
[10]
Annis MG, Ouellet V, Rennhack JP, et al.Integrin-uPAR signaling leads to FRA-1phosphorylation and enhanced breast cancer invasion[J]. Breast Cancer Research, 2018, 20(1): 9.
[11]
孙龙,李旭军. 乳腺癌CAF中IL-6介导的上皮间质转化及其在肿瘤三苯氧胺耐受中的作用[J]. 中国妇幼保健,2018,33(9):2109-2112.
[12]
胡晓红,柏华,段娟娟,等. 反馈激活STAT3调控HER2阳性乳腺癌细胞拉帕替尼耐药的机制[J]. 肿瘤防治研究,2019,46(4):305-310.
[13]
Yang Y, Quan LL, Ling Y. RBMS3 Inhibits the Proliferation and Metastasis of Breast Cancer Cells[J]. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2018, 26(1): 9-15.
[14]
钟瑾怡,成丛丛,徐金媛,等. 多柔比星通过Stat3-Oct-4/CD44途径诱导三阴性乳腺癌4T1细胞干性的产生[J]. 中国病理生理杂志,2019,35(2):360-364.
[15]
郑丽坤,张磊,姜海平. STAT3传导通路在瘦素介导的上调乳腺癌细胞存活素中的作用[J]. 中国煤炭工业医学杂志,2018,21(2):166-169.
[16]
戴少华,丁云,曾凡宁,等. 石见穿总甾醇调控乳腺癌细胞增殖分化凋亡的研究[J]. 临床和实验医学杂志,2018,17(12):1268-1271.
[17]
Bai X-Y, Li SJ, Wang ML, et al.Kruppel-like factor 9 Down-Reg μlates Matrix Metalloproteinase 9 Transcription and Suppresses Human Breast Cancer Invasion[J]. Cancer Letters, 2017, 412(2): 224-235.
[18]
邓程伟,吴进盛,何淑波,等. STIM1对乳腺癌细胞存活与增殖的影响及初步机制分析[J].中国免疫学杂志,2018,34(5):681-687.
[19]
严玉荣,赵晨辰,杨睿,等.IFN-γ激活ERK/Jak2-STAT信号通路诱导乳腺癌细胞过表达PD-L1和上皮-间质转化[J].生物工程学报,2018,34(12):2007-2015.
[20]
马丽,石荣珍,邓九零,等.胸腺素β4和β10表达促进小鼠乳腺癌细胞转移[J].中国药理学与毒理学杂志,2018,32(7):565-572.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要